Prescriber Criteria Form Doptelet 2024 PA Fax 2586-A v1 010124.docx Doptelet (avatrombopag) Coverage Determination
This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Doptelet (avatrombopag).

Drug Name: Doptelet (avatrombopag)

Patient Name:		
Patient ID:		
Patient DOB:	**Patient Phone:**	
Prescriber Name:		
Prescriber Address:		
City:	**State:**	**Zip:**
Prescriber Phone:	**Prescriber Fax:**	
Diagnosis:	**ICD Code(s):**	

Please circle the appropriate answer for each question.			
1	Does the patient have a diagnosis of thrombocytopenia associated with chronic liver disease? [If no, then skip to question 5.]	Yes	No
2	Is the patient scheduled to undergo a procedure? [If no, then no further questions.]	Yes	No
3	Prior to the scheduled procedure, is the patient's untransfused platelet count less than 50,000 cells per microliter (mcL)? [If no, then no further questions.]	Yes	No
4	Is the patient 18 years of age or older? [No further questions.]	Yes	No
5	Is the requested drug prescribed for the treatment of thrombocytopenia in a patient with chronic immune thrombocytopenia (ITP)? [If no, then no further questions.]	Yes	No
6	Is the request for continuation of therapy? [If no, then skip to question 9.]	Yes	No
7	Did the patient's platelet count respond to the requested drug as evidenced by either of the following: A) the current platelet count is less than or equal to 200,000 cells per microliter (mcL), B) the current platelet count is greater than 200,000 cells per microliter	Yes	No

	(mcL) and less than or equal to 400,000 cells per microliter (mcL) and dosing will be adjusted to a platelet count sufficient to avoid clinically important bleeding? [If no, then no further questions.]		
8	Is the patient 18 years of age or older? [No further questions.]	Yes	No
9	Has the patient had an inadequate response or is intolerant to a prior therapy such as corticosteroids or immunoglobulins? [If no, then no further questions.]	Yes	No
10	Was the untransfused platelet count at any point prior to the initiation of the requested medication less than 30,000 cells per microliter (mcL) OR 30,000 to 50,000 cells per microliter (mcL) with symptomatic bleeding or risk factors for bleeding (e.g., undergoing a medical or dental procedure where blood loss is anticipated, comorbidities such as peptic ulcer disease and hypertension, anticoagulation therapy, profession or lifestyle that predisposes patient to trauma)? [If no, then no further questions.]	Yes	No
11	Is the patient 18 years of age or older?	Yes	No

Comments:	_____

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: _____ **Date:**_____